IMC Chicago’s Roivant Sciences ROIV Stock Holding History

IMC Chicago’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.43M	Buy	68,630 +36,411	+113%	+$1.08M	﹤0.01%	2822
2026 Q1	$892K	Buy	+32,219	New	+$828K	﹤0.01%	3391

Other funds holding ROIV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return

IMC Chicago's ROIV Position: Q2 2026 in Review

IMC Chicago increased its Roivant Sciences (ROIV) stake by 113% in Q2 2026, buying an estimated $1.08M and bringing the position to 68,630 shares worth $2.43M. The position accounts for ﹤0.01% of the portfolio, ranked #2822.

IMC Chicago first reported a position in ROIV in Q1 2026 and has held it in 2 quarters since. 354 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

IMC Chicago held 68,630 shares of Roivant Sciences worth $2.43M as of Q2 2026.
IMC Chicago bought 36,411 Roivant Sciences shares in Q2 2026, an estimated $1.08M.
Roivant Sciences made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #2822 holding.
IMC Chicago first reported a position in Roivant Sciences in Q1 2026 and has held it in 2 quarters since.
354 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.